NewLink Genetics to Participate in the Upcoming Stifel, Jeffries, and Piper Jaffray Healthcare Conferences

AUSTIN, Texas, Nov. 17, 2014 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that it will present at the following conferences:

  • At 9:45 am on Tuesday, November 18, 2014, NewLink will present at the Stifel Healthcare Conference in New York.
  • At 2:20 pm on Thursday, November 20, 2014, NewLink will present at the Jeffries Global Healthcare Conference in London.
  • At 11:10 am on Tuesday, December 2, 2014, NewLink will present at the Piper Jaffray Annual Healthcare Conference in New York.

All conference times listed are local time. These presentations will not be webcast.

About NewLink Genetics Corporation

NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit

Cautionary Note Regarding Forward-Looking Statements

Statements made at the upcoming conference may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results. Forward-looking factors that may be discussed include, but are not limited to, future financial performance, new product development, governmental approvals and market potential. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that NewLink makes due to a number of important factors, including those risks discussed in "Risk Factors" and elsewhere in NewLink's Annual Report on Form 10-K for the period ended December 31, 2013, and subsequent filings with the Securities and Exchange Commission. These forward-looking statements are made only as the date thereof, and the Company undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Investor Contact: Jack Henneman Chief Financial Officer (515) 598-2561 Investor@linkp.comSource:NewLink Genetics Corporation